Effects of secukinumab combined with tretinoin 
on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris

Yong Chen; Mei Yi; Xiaoyan Pang; Mengfei Du; Haizhou Chen; Zhenshu Li

doi:10.5114/ada.2023.135605

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2024
vol. 41

Send email

Copy url:

abstract:

Original paper

Effects of secukinumab combined with tretinoin on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris

Yong Chen

¹

,

Mei Yi

¹

,

Xiaoyan Pang

²

,

Mengfei Du

¹

,

Haizhou Chen

¹

,

Zhenshu Li

¹

Department of Dermatology, Central People’s Hospital of Zhanjiang, Zhanjiang, Guangdong Province, China
Department of Pathology, Central People’s Hospital of Zhanjiang, Zhanjiang, Guangdong Province, China

Adv Dermatol Allergol 2024; XLI (1): 113-120

DOI: https://doi.org/10.5114/ada.2023.135605

Online publish date: 2024/03/15

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Chen Y, Yi M, Pang X, Du M, Chen H, Li Z. Effects of secukinumab combined with tretinoin 
on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2024;41(1):113-120. doi:10.5114/ada.2023.135605.

APA

Chen, Y., Yi, M., Pang, X., Du, M., Chen, H.,  & Li, Z. (2024). Effects of secukinumab combined with tretinoin 
on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 41(1), 113-120. https://doi.org/10.5114/ada.2023.135605

Chicago

Chen, Yong, Mei Yi, Xiaoyan Pang, Mengfei Du, Haizhou Chen,  and Zhenshu Li. 2024. "Effects of secukinumab combined with tretinoin 
on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 41 (1): 113-120. doi:10.5114/ada.2023.135605.

Harvard

Chen, Y., Yi, M., Pang, X., Du, M., Chen, H.,  and Li, Z. (2024). Effects of secukinumab combined with tretinoin 
on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 41(1), pp.113-120. https://doi.org/10.5114/ada.2023.135605

MLA

Chen, Yong et al. "Effects of secukinumab combined with tretinoin 
on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 41, no. 1, 2024, pp. 113-120. doi:10.5114/ada.2023.135605.

Vancouver

Chen Y, Yi M, Pang X, Du M, Chen H, Li Z. Effects of secukinumab combined with tretinoin 
on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2024;41(1):113-120. doi:10.5114/ada.2023.135605.

Introduction:
Psoriasis is a T cell-mediated polygenic chronic inflammatory disease. Interleukin (IL)-17A plays a major role in psoriasis pathogenesis. Secukinumab is a high-affinity human monoclonal antibody against IL-17A.

Aim:
This article explored efficacy and safety of secukinumab plus tretinoin in moderate to severe psoriasis (MSP) vulgaris, and assessed metabolism, liver function, and inflammation.

Material and methods:
A total of 135 patients diagnosed with moderate or severe psoriasis vulgaris were enrolled and randomized into three groups at a 1 : 1 : 1 ratio, receiving treatment with rretinoin, secukinumab, or combination therapy for a duration of 16 weeks. Psoriasis area and severity index (PASI) scores, serum T lymphocyte subsets, glucose, lipid, and uric acid (UA) metabolism, liver enzymes, and inflammatory factors (IFs) were measured.

Results:
Following the therapy, subjects had decreased PASI scores, increased serum CD3+, CD4+, and CD4+/CD8+, decreased serum CD8+, and decreased serum UA and IL-2, IL-6, IL-23, interferon-g (IFN-g), and tumor necrosis factor (TNF)-a (p < 0.05). Total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, apolipoproteins A1, B, fasting blood glucose, alanine transaminase, aspartate transaminase, and alkaline phosphatase had no obvious differences among the subjects (p > 0.05). As against the Tretinoin and the Secukinumab groups, the PASI score was visiblysmaller, the changes in serum T lymphocyte subsets were more obvious, and serum UA and IFs were lower in the Combination group following the therapy (p < 0.05).

Conclusions:
Secukinumab combined with tretinoin is more effective in MSP vulgaris, which can visibly reduce inflammatory response without affecting glucose and lipid metabolism and liver function.

keywords:

Effects of secukinumab combined with tretinoin on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris

Yong Chen 1 , Mei Yi 1 , Xiaoyan Pang 2 , Mengfei Du 1 , Haizhou Chen 1 , Zhenshu Li 1

psoriasis vulgaris, secukinumab, tretinoin, metabolism, liver enzymology, inflammatory factors

Yong Chen

¹

,

Mei Yi

¹

,

Xiaoyan Pang

²

,

Mengfei Du

¹

,

Haizhou Chen

¹

,

Zhenshu Li

¹